Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 1040143 | 4.75 |
09:34 ET | 41625 | 4.75 |
09:36 ET | 24429 | 4.73 |
09:38 ET | 27895 | 4.75 |
09:39 ET | 5338 | 4.765 |
09:41 ET | 13104 | 4.765 |
09:43 ET | 6520 | 4.775 |
09:45 ET | 9480 | 4.765 |
09:48 ET | 14717 | 4.77 |
09:50 ET | 17190 | 4.7566 |
09:52 ET | 13383 | 4.765 |
09:54 ET | 8527 | 4.775 |
09:56 ET | 10157 | 4.765 |
09:57 ET | 4069 | 4.765 |
09:59 ET | 10395 | 4.755 |
10:01 ET | 6734 | 4.765 |
10:03 ET | 37961 | 4.775 |
10:06 ET | 16341 | 4.7651 |
10:08 ET | 7700 | 4.765 |
10:10 ET | 4326 | 4.765 |
10:12 ET | 18210 | 4.765 |
10:14 ET | 22014 | 4.755 |
10:15 ET | 54121 | 4.76 |
10:17 ET | 1925 | 4.76 |
10:19 ET | 28985 | 4.765 |
10:21 ET | 4400 | 4.765 |
10:24 ET | 9569 | 4.77 |
10:26 ET | 6375 | 4.775 |
10:28 ET | 13975 | 4.78 |
10:30 ET | 11784 | 4.78 |
10:32 ET | 43657 | 4.77 |
10:33 ET | 12877 | 4.775 |
10:35 ET | 20280 | 4.775 |
10:37 ET | 41752 | 4.775 |
10:39 ET | 23238 | 4.77 |
10:42 ET | 3700 | 4.765 |
10:44 ET | 42328 | 4.765 |
10:46 ET | 12881 | 4.765 |
10:48 ET | 67363 | 4.765 |
10:50 ET | 3301 | 4.77 |
10:51 ET | 26503 | 4.78 |
10:53 ET | 9080 | 4.775 |
10:55 ET | 81050 | 4.78 |
10:57 ET | 8294 | 4.78 |
11:00 ET | 31716 | 4.765 |
11:02 ET | 21539 | 4.755 |
11:04 ET | 48845 | 4.755 |
11:06 ET | 9344 | 4.75 |
11:08 ET | 5850 | 4.755 |
11:09 ET | 79083 | 4.765 |
11:11 ET | 31366 | 4.755 |
11:13 ET | 35436 | 4.75 |
11:15 ET | 34668 | 4.735 |
11:18 ET | 64757 | 4.72 |
11:20 ET | 15146 | 4.725 |
11:22 ET | 27395 | 4.7294 |
11:24 ET | 95323 | 4.715 |
11:26 ET | 75739 | 4.73 |
11:27 ET | 2700 | 4.73 |
11:29 ET | 24830 | 4.735 |
11:31 ET | 41751 | 4.72 |
11:33 ET | 20652 | 4.72 |
11:36 ET | 14078 | 4.735 |
11:38 ET | 35718 | 4.735 |
11:40 ET | 44798 | 4.735 |
11:42 ET | 24100 | 4.735 |
11:44 ET | 39013 | 4.735 |
11:45 ET | 16316 | 4.735 |
11:47 ET | 21746 | 4.735 |
11:49 ET | 33210 | 4.735 |
11:51 ET | 41511 | 4.725 |
11:54 ET | 29916 | 4.725 |
11:56 ET | 734 | 4.72 |
11:58 ET | 18343 | 4.73 |
12:00 ET | 11298 | 4.735 |
12:02 ET | 4047 | 4.735 |
12:03 ET | 9640 | 4.735 |
12:05 ET | 11687 | 4.735 |
12:07 ET | 16439 | 4.745 |
12:09 ET | 28496 | 4.76 |
12:12 ET | 4749 | 4.76 |
12:14 ET | 93317 | 4.765 |
12:16 ET | 3402 | 4.765 |
12:18 ET | 119286 | 4.775 |
12:20 ET | 65495 | 4.775 |
12:21 ET | 14813 | 4.78 |
12:23 ET | 102718 | 4.785 |
12:25 ET | 124798 | 4.805 |
12:27 ET | 42016 | 4.805 |
12:30 ET | 17347 | 4.805 |
12:32 ET | 8494 | 4.81 |
12:34 ET | 6117 | 4.8094 |
12:36 ET | 15185 | 4.805 |
12:38 ET | 66392 | 4.805 |
12:39 ET | 119531 | 4.795 |
12:41 ET | 179248 | 4.795 |
12:43 ET | 110228 | 4.795 |
12:45 ET | 29635 | 4.8 |
12:48 ET | 43515 | 4.795 |
12:50 ET | 26126 | 4.795 |
12:52 ET | 10856 | 4.8 |
12:54 ET | 47490 | 4.81 |
12:56 ET | 32264 | 4.79 |
12:57 ET | 16170 | 4.785 |
12:59 ET | 17774 | 4.78 |
01:01 ET | 15543 | 4.771 |
01:03 ET | 72686 | 4.805 |
01:06 ET | 8124 | 4.805 |
01:08 ET | 5890 | 4.81 |
01:10 ET | 50154 | 4.805 |
01:12 ET | 4854 | 4.8 |
01:14 ET | 7927 | 4.805 |
01:15 ET | 2900 | 4.805 |
01:17 ET | 5363 | 4.804 |
01:19 ET | 51087 | 4.795 |
01:21 ET | 17083 | 4.8075 |
01:24 ET | 58539 | 4.81 |
01:26 ET | 14154 | 4.805 |
01:28 ET | 33437 | 4.795 |
01:30 ET | 11377 | 4.79 |
01:32 ET | 4235 | 4.795 |
01:33 ET | 30788 | 4.8 |
01:35 ET | 119059 | 4.8 |
01:37 ET | 68453 | 4.8 |
01:39 ET | 15480 | 4.8 |
01:42 ET | 15979 | 4.8 |
01:44 ET | 90514 | 4.8 |
01:46 ET | 47659 | 4.785 |
01:48 ET | 10319 | 4.775 |
01:50 ET | 7104 | 4.77 |
01:51 ET | 30582 | 4.78 |
01:53 ET | 13231 | 4.785 |
01:55 ET | 60441 | 4.7783 |
01:57 ET | 2880 | 4.77 |
02:00 ET | 37290 | 4.775 |
02:02 ET | 4449 | 4.775 |
02:04 ET | 69288 | 4.76 |
02:06 ET | 12043 | 4.765 |
02:08 ET | 12008 | 4.765 |
02:09 ET | 19730 | 4.765 |
02:11 ET | 9169 | 4.765 |
02:13 ET | 15269 | 4.765 |
02:15 ET | 92502 | 4.79 |
02:18 ET | 104234 | 4.78 |
02:20 ET | 9205 | 4.7701 |
02:22 ET | 38180 | 4.79 |
02:24 ET | 18626 | 4.795 |
02:26 ET | 19858 | 4.8 |
02:27 ET | 11578 | 4.795 |
02:29 ET | 64549 | 4.785 |
02:31 ET | 5158 | 4.775 |
02:33 ET | 1900 | 4.774 |
02:36 ET | 29303 | 4.765 |
02:38 ET | 9595 | 4.765 |
02:40 ET | 28997 | 4.785 |
02:42 ET | 15051 | 4.785 |
02:44 ET | 33776 | 4.8 |
02:45 ET | 19400 | 4.795 |
02:47 ET | 24632 | 4.8 |
02:49 ET | 190123 | 4.8075 |
02:51 ET | 21985 | 4.805 |
02:54 ET | 16762 | 4.805 |
02:56 ET | 71831 | 4.815 |
02:58 ET | 40155 | 4.82 |
03:00 ET | 13005 | 4.815 |
03:02 ET | 86359 | 4.805 |
03:03 ET | 6745 | 4.805 |
03:05 ET | 37567 | 4.795 |
03:07 ET | 44316 | 4.795 |
03:09 ET | 44634 | 4.785 |
03:12 ET | 14994 | 4.795 |
03:14 ET | 56132 | 4.795 |
03:16 ET | 12080 | 4.8 |
03:18 ET | 19277 | 4.795 |
03:20 ET | 41891 | 4.795 |
03:21 ET | 6300 | 4.795 |
03:23 ET | 21167 | 4.795 |
03:25 ET | 45549 | 4.785 |
03:27 ET | 8701 | 4.785 |
03:30 ET | 77363 | 4.8 |
03:32 ET | 140592 | 4.795 |
03:34 ET | 128776 | 4.785 |
03:36 ET | 35715 | 4.8 |
03:38 ET | 40678 | 4.795 |
03:39 ET | 61330 | 4.8 |
03:41 ET | 31802 | 4.795 |
03:43 ET | 34762 | 4.8 |
03:45 ET | 65209 | 4.795 |
03:48 ET | 26961 | 4.8 |
03:50 ET | 96464 | 4.8 |
03:52 ET | 155619 | 4.805 |
03:54 ET | 185867 | 4.815 |
03:56 ET | 274224 | 4.79 |
03:57 ET | 196461 | 4.755 |
03:59 ET | 10943816 | 4.71 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.9B | -13.1x | --- |
Edgewise Therapeutics Inc | 2.8B | -18.4x | --- |
Celldex Therapeutics Inc | 2.7B | -15.0x | --- |
CG Oncology Inc | 2.6B | -33.4x | --- |
Xenon Pharmaceuticals Inc | 3.1B | -14.7x | --- |
Apogee Therapeutics Inc | 3.1B | -26.0x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9B |
---|---|
Revenue (TTM) | $1.4M |
Shares Outstanding | 602.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.50 |
EPS | $-0.36 |
Book Value | $0.46 |
P/E Ratio | -13.1x |
Price/Sales (TTM) | 2,081.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -16,559.94% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.